

RESEARCH ARTICLE

Acetylcholinesterase and carbonic anhydrase isoenzymes I and II inhibition profiles of taxifolin

Hulya Gocer¹, Fevzi Topal², Meryem Topal², Murat Küçük³, Dilek Teke³, İlhami Gülçin^{3,4}, Saleh H. Alwasel⁴, and Claudiu T. Supuran^{5,6}

¹Central Researching Laboratory, Agri Ibrahim Cecen University, Agri, Turkey, ²Department of Medical Services and Techniques, Vocational School of Health Services, Gumushane University, Gumushane, Turkey, ³Department of Chemistry, Faculty of Sciences, Atatürk University, Erzurum, Turkey, ⁴Zoology Department, College of Science, Fetal Programming of Diseases Research Chair, King Saud University, Riyadh, Saudi Arabia, ⁵Dipartimento di Chimica Ugo Schiff, Università degli Studi di Firenze, Sesto Fiorentino, Firenze, Italy, and ⁶Neurofarba Department, Section of Pharmaceutical and Nutraceutical Sciences, Università degli Studi di Firenze, Sesto Fiorentino, Florence, Italy

Abstract

Taxifolin, also known as dihydroquercetin, is a flavonoid commonly found in plants. Carbonic anhydrase (CA, EC 4.2.1.1) plays an important role in many critical physiological events including carbon dioxide (CO₂)/bicarbonate (HCO₃[−]) respiration and pH regulation. There are 16 known CA isoforms in humans, of which human hCA isoenzymes I and II (hCA I and II) are ubiquitous cytosolic isoforms. In this study, the inhibition properties of taxifolin against the slow cytosolic isoenzyme hCA I, and the ubiquitous and dominant rapid cytosolic isoenzyme hCA II were studied. Taxifolin, as a naturally bioactive flavonoid, has a K_i of 29.2 nM against hCA I, and 24.2 nM against hCA II. For acetylcholinesterase enzyme (AChE) inhibition, K_i parameter of taxifolin was determined to be 16.7 nM. These results clearly show that taxifolin inhibited both CA isoenzymes and AChE at the nM levels.

Keywords

Acetylcholinesterase, carbonic anhydrase, enzyme inhibition, enzyme purification, taxifolin

History

Received 10 March 2015
Revised 24 March 2015
Accepted 27 March 2015
Published online 20 April 2015

Introduction

In recent years, natural flavonoids have attracted significant interests in the scientific arena because of their versatility of uses and health-promoting effects. Flavonoids are important compounds that can be found in many plants, including edible fruits and vegetables. Flavonoids act as efficient antioxidants because of their ability to chelate transition metal ions, to scavenge free radicals and to interact with enzymes^{1–3}. It was reported that *in vivo* and *in vitro* studies of flavonoids showed that they have a positive impact on many important diseases, such as those affecting cardiovascular system^{1,3}.

Phenolic compounds contain at least a hydroxyl group (–OH) bonded to aromatic ring and are mildly acidic^{4–11}. Phenolic compounds are classified as simple phenols or polyphenols based on the number of phenol units in the molecule. This chemical class in terms of biological and pharmaceutical is very reactive^{12–24}.

Taxifolin (dihydroquercetin) is a representative flavonoid compound. It is present in the plants from the *Pinus* genus and it is also found in citrus fruits and milk thistle seeds²⁵. Taxifolin has many a large area of biological effects, including anti-inflammatory, hepatoprotective effects and antitumor effects²⁶.

More important, taxifolin produces effective antioxidant effects, which contribute to its cardiovascular protective effects. Due to the reducing properties of its hydroxyl groups, taxifolin exhibits antioxidant activity and reacts with free radicals³.

Researchers have demonstrated that taxifolin decreased the production of lipid radicals in a concentration-dependent manner and reduced the peroxidase activity of the complex of cytochrome c combined with dioleoyl cardiolipin, which is critical for the onset of apoptosis. Taxifolin also ameliorated cerebral ischemia-reperfusion injury by inhibiting oxidative enzymes and reducing the overproduction of ROS^{27,28}. Taxifolin inhibited recombinant human aldose reductase and the accumulation of sorbitol in human erythrocyte in diabetes. Taxifolin also retained the clarity of rat lenses incubated with glucose, suggesting that taxifolin might be effective in preventing osmotic stress in hyperglycemia²⁹. However, there has been little work on possible beneficial effects of taxifolin for diabetic cardiomyopathy. Caspase enzymes are important factors for modulating the apoptotic cascade. These results have demonstrated that caspase-3 and caspase-9 activities were significantly inhibited by taxifolin³⁰. Additionally, it was shown that taxifolin decreases the angiotensin-converting enzyme activity in the aorta of aging rats³¹. Studies have shown the modulatory effects of flavonoids upon multiple enzymes involved in xenobiotic metabolism such as on various cytochrome P450 monooxygenase isoforms and phase II conjugation enzymes and on membrane transport systems including in drug excretion^{32–35}.


Address for correspondence: Prof. Dr. İlhami Gülçin, Department of Chemistry, Faculty of Sciences, Atatürk University, Erzurum 25240, Turkey. Tel: +90 442 2314375. Fax: +90 442 2314109. E-mail: igulcin@atauni.edu.tr, igulcin@yahoo.com

Carbonic anhydrase enzymes (CAs) are ubiquitous in all the living organisms. They have crucial physiological and pathological roles such as in fluid balance, calcification, pH regulation, carboxylation reactions, tumorigenicity, bone resorption, the synthesis of HCO_3^- and in many other pathophysiological processes^{36–39}. The CA catalyzes the reversible hydration of carbon dioxide (CO_2) and water (H_2O) to bicarbonate (HCO_3^-) and a proton (H^+)^{40–46}.



An enzyme inhibitor is a molecule that engages to an enzyme and decreases its activity. An inhibitor can prevent a substrate from binding the active site of the enzyme, thus hindering catalysis. It is well known that CA inhibitors (CAIs) bind to a catalytic zinc ion (Zn^{2+}) in the active site of CA isoenzymes and block their activity^{47–52}. The clinical use of CAIs had been established as antiglaucoma, and as anticonvulsant agents⁴⁸, diuretics⁴² and antiobesity drugs^{53–55} in the management of mountain sickness, gastric and duodenal ulcers, neurological disorders or osteoporosis⁴⁷. Additionally, CAIs have recently been used as hypoxic tumors management agent^{56,57}. The first clinically used heterocyclic and aromatic sulfonamides were clinically used derivatives of acetazolamide (AZA), a known CAI^{58,59}. AZA is an inhibitor of CA and used for glaucoma, idiopathic intracranial hypertension, epilepsy and altitude sickness. To regenerate the basic form of CA isoenzyme, a H^+ is transferred from the active site to the solvent. This H^+ transportation may be supported by active site residues or by present buffers in the reaction medium. The fourth position is occupied by H_2O at an acidic pH and is catalytically inactive. At higher pH, a H_2O molecule binds to Zn^{2+} within the CA active site. Then, this proton transfer reaction transfers a H^+ to the solvent, leaving an $-\text{OH}$ group^{47,49,50,52,57}.

Alzheimer's disease (AD) is a neurological disorder in which the patient suffers from memory loss and impaired cognitive abilities. AD is a chronic neurological disorder in which the patient suffers from loss impaired cognitive abilities, deficits in activities of daily living and behavioral disturbances^{37,60}. According to the cholinergic hypothesis, memory impairment in patients suffering from AD results from decreased levels of the neurotransmitter acetylcholine (ACh) in the cortex³⁹. Acetylcholinesterase (AChE, EC: 3.1.1.7) is a hydrolase that plays a key role in cholinergic transmission through catalyzing the rapid hydrolysis of the neurotransmitter ACh⁶¹. AChE is a special carboxylic ester hydrolase that hydrolyses the esters of choline^{39,60} to produce acetic acid and choline⁶².



AChE is found in high concentrations in the brain and in erythrocytes⁶³. AChE is a necessary enzyme for the nervous system. AChE inhibitors (AChEI) are used in the treatment of several neuromuscular diseases, and were studied for treatment of AD^{39,61,64}. The use of AChEI to block the cholinergic degradation of ACh is therefore considered to be a promising approach for the treatment of AD. Natural products might slow the progression of AD by simultaneously protecting neurons from oxidative stress and by acting as an AChEI⁶⁵. Certain organophosphorus and carbamate derivatives are known to be the best inhibitors of AChE

catalytic activity⁶⁶. Carbamate pesticides show their toxicity by irreversibly modifying the catalytic serine residue of AChE, and the inhibiting the AChE⁶⁷. Recently, several studies supported that many active compounds from plant origins, including anthocyanins and terpenoids have AChE inhibition activity^{68,69}. Additionally, some studies demonstrated that grape and blueberry anthocyanin^{70,71}, grape skin anthocyanin⁷² lycodine-type alkaloids from *Lycopodium casuarinoides*⁷³ have neuroprotective roles.

In this study, we identify the potential inhibition profile and associated mechanisms of taxifolin for human CA isoenzymes I and II (hCA I and II) and for AChE which are widely used enzyme in pharmacological industry.

Experimental

Purification of CA isoenzymes

Both hCA isoenzymes were purified by sepharose-4B-L-tyrosine-sulphanilamide affinity chromatography^{74–77}. For this purpose, the lysate was adjusted with Tris buffer to pH 8.7 and applied to the affinity column. Then, protein content in the eluates was recorded spectrophotometrically at wavelength of 280 nm. SDS-PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis) was performed after purification of the enzymes. The isoenzymes purities were controlled by SDS-PAGE, and a single band was found for each CA isoenzyme⁷⁸. SDS-PAGE method has been detailed described previously⁷⁹ and was performed using acrylamide in the running (10%) and the stacking gel (3%), with 0.1% SDS^{80,81}.

Determination of CA isoenzymes activities

Both CA isoenzyme activities were performed according to the procedure of Verpoorte et al.⁸² and as described previously by our group^{81,83}. The absorbance change was spectrophotometrically reordered at 348 nm during 3 min at room temperature (25 °C). One unit of enzyme activity is expressed as 1 mol/L of released *p*-nitrophenol per minute at 25 °C⁸⁴. The protein quantity was spectrophotometrically determined at 595 nm during purification steps by the Bradford method⁸⁵. Bovine serum albumin was used as the standard protein^{86,87}.

CA isoenzymes inhibition assay

The inhibition property of taxifolin against both CA isoenzymes was determined by hydrolysis of *p*-nitrophenylacetate to *p*-nitrophenol. The later molecule can be monitored spectro-

photometrically⁴⁹. The CO_2 hydration reaction catalyzed by CA was first observed in the absence of taxifolin; the resulting rates were measured and used as a control for the CA isoenzymes. Also, the same reaction was measured in the presence of taxifolin. The percent inhibition was determined with $(\%) = [100 - (A_s/A_c) \times 100]$, where A_s is the absorbance of the sample containing taxifolin and A_c is the absorbance of the control sample. The activity $(\%)$ –[taxifolin] graphs were drawn and the half maximal inhibitory concentration (IC_{50}) values of taxifolin demonstrated $>50\%$ inhibition of CA isoenzymes were calculated after

suitable dilutions. K_i values for taxifolin were determined for both isoenzymes. For this purpose to determine the K_i values, taxifolin was tested at three different concentrations. K_i is the binding affinity constant of the taxifolin to CA isoenzymes. NPA was used as the substrate at five different concentrations, and Lineweaver–Burk curves were drawn⁸⁸ in detail as described previously^{89–92}.

Acetylcholinesterase inhibition assay

Acetylcholinesterase enzyme inhibition assay was determined on commercially available purified AChE (Product no: C3389-Sigma–Aldrich, St. Louis, MO) from electric gel (*Electrophorus electricus*) based on the method of Ellman procedure⁹³. Acetylthiocholine iodide (ATCI) was used as the substrate. Also, 5,5-dithiobis(2-nitrobenzoic) acid (DTNB) was used for the monitoring of AChE activity. Briefly, 150 μ l of sodium phosphate buffer (0.1 M, pH 8.0), 10 μ l test compound solution and 20 μ l of enzyme solution (0.09 units/ml) were mixed and incubated for 15 min at room temperature. Then, 10 μ l of DTNB (10 mM) was transferred and the reaction was initiated by the addition of substrate solution (10 μ l of ATCI, 14 mM solution). The hydrolysis of the ATCI was measured by the formation of the product, 5-thio-2-nitrobenzoate, which is released by AChE hydrolysis. Absorbance of final solution was spectrophotometrically measured at 412 nm (Beckman Coulter DU 730) after 10-min incubation. Tacrine, a standard AChE inhibitor, was used as a positive control. The percent of AChE inhibition was calculated as follows:

$$\text{Inhibition (\%)} = 100 - [A_S/A_C] \times 100$$

where A_S is the absorbance of the sample containing taxifolin and A_C is the absorbance of the control sample.

Results and discussion

Carbonic anhydrases catalysis the crucial pathophysiological processes that are connected with $\text{CO}_2/\text{HCO}_3^-$ transport and homeostasis, biosynthetic reactions including gluconeogenesis, ureagenesis and lipogenesis, respiration, calcification, tumorigenicity, electrolyte secretion in a variety of tissues and organs, and bone resorption⁹⁴. Phenolic compounds are a class of chemicals containing of a –OH bonded directly to an aromatic hydrocarbon group and are categorized either as simple phenols or as polyphenols depending on the number of phenol units in the molecule²⁴. Recently, a lot of phenolic acid, phenols and phenolic derivatives were investigated in detail as inhibitors of the Zn^{2+} -containing CA isoenzymes by our group^{95–99}. It was reported all CA isoforms are inhibited by three different mechanisms: (i) inhibition by coordination of the inhibitor to the Zn^{2+} located in the active site of CA isoenzymes, thereby replacing the Zn^{2+} -bound $\text{H}_2\text{O}/\text{OH}$, which leads to a tetrahedral geometry for Zn^{2+} . This geometry can also arise by the addition of an inhibitor

to the metal coordination sphere when the Zn^{2+} has trigonal bipyramidal geometry¹. (ii) Inhibition by anchoring of the inhibitor to the Zn^{2+} -bound solvent molecule, i.e. an $\text{H}_2\text{O}/\text{OH}$. Phenolic compounds and polyamine molecules can bind to CA in this way, as shown schematically for phenol or (iii) inhibition by inhibitor occlusion of the active site or activator-binding site of CA^{100–102}. Thus, by binding in a non-classical way to CAs, phenols and their derivatives provide interesting leads for identifying novel types of CAIs. Taxifolin has two classical structural characteristics in one molecule: phenols and ketone.

It has been reported that phenols act as an inhibitors of the Zn^{2+} -containing CA isoenzymes¹⁰³. Phenol binds to CA in a diverse manner when compared to the classic sulfonamide inhibitors. Sulfonamides coordinate to the Zn^{2+} ion in the CA active site by replacing the fourth non-protein ligand, which is typically an H_2O molecule or a –OH ion. By binding in a non-classical way to CAs, phenols and their derivatives constitute interesting leads for identifying novel types of CAIs^{94,100,102}. In the present study, we report the inhibition profiles of taxifolin against the slower cytosolic isoform, hCA I and the more rapid isoenzyme hCA II. Taxifolin showed effective inhibition of both isoforms (Table 1).

To describe inhibitory effects, researchers often list an IC_{50} value; however, a more suitable measure is the K_i constant. K_i values were calculated from Lineweaver–Burk graphs (Figures 1, 2 and 3), and both the K_i and IC_{50} parameters of the taxifolin were determined in this study. The Lineweaver–Burk plot is a graphical representation of the Lineweaver–Burk equation of enzyme kinetics¹⁰⁴. The plot provides a useful graphical method for analysis of the Michaelis–Menten equation:

$$V = V_{\max} + \frac{[S]}{K_m + [S]}$$

Taking the reciprocal gives

$$\frac{1}{V} = \frac{K_m + [S]}{V_{\max}[S]} = \frac{K_m}{V_{\max}} \times \frac{1}{[S]} + \frac{1}{V_{\max}}$$

where V is the reaction velocity, K_m is the Michaelis–Menten constant, $V_{\max}$ is the maximum reaction velocity and $[S]$ is the substrate concentration.

As shown in Table 1 and Figure 1, the IC_{50} and K_i values were found for taxifolin against both CA isoenzymes. For the cytosolic isoenzyme hCA I, taxifolin had an IC_{50} value of 27.72 nM and a K_i value of 29.20 ± 2.85 nM (Table 1). On the other hand, AZA is a hCA I that is used for the medical treatment of glaucoma, altitude sickness, epileptic seizure, idiopathic intracranial hypertension, central sleep apnoea, cystinuria, periodic paralysis and dural ectasia. AZA was extensively used as positive control for both CA isoenzymes. In the present study, AZA demonstrated IC_{50} values of 315.52 and 123.53 nM against hCA I and II,

Table 1. The inhibition profiles of taxifolin on purified hCA I and II from human erythrocytes by sepharose-4B-L-tyrosine-sulfanilamide affinity chromatography and inhibition of AChE purified from electric gel (*Electrophorus electricus*).


Taxifolin	Kinetic parameters	hCA I	hCA II	AChE
	IC_{50} (nM)	27.7	43.3	30.1
	R^2	0.9858	0.9682	0.9723
	K_i (nM)	29.2 ± 2.9	24.2 ± 6.5	16.7 ± 3.9
	Inhibition type	Non-competitive	Non-competitive	Non-competitive

Figure 1. Determination of the half maximal inhibitory concentration (IC_{50}) (A) and inhibition constant (K_i) values (B) of taxifolin for human erythrocyte carbonic anhydrase I isoenzyme (hCA I) by using a Lineweaver–Burk graph.




Figure 2. Determination of the half maximal inhibitory concentration (IC_{50}) (A) and inhibition constant (K_i) values (B) of taxifolin for human erythrocyte carbonic anhydrase II isoenzyme (hCA II) by using a Lineweaver–Burk graph.





Figure 3. Determination of the half maximal inhibitory concentration (IC_{50}) value (A) and inhibition constant (K_i) value (B) of taxifolin for acetylcholinesterase enzyme (AChE) by using a Lineweaver–Burk graph.



respectively. On the other hand, its K_i values for both isoenzymes were found as 184.34 and 61.12 nM, respectively. These results clearly show that taxifolin had more CA isoenzyme inhibitor effects than that of AZA.

As seen in Figure 2, for the physiologically predominant CA II, taxifolin had an IC_{50} value of 43.31 ± 6.45 nM and a K_i value of 24.15 ± 6.45 nM. Many studies have shown that the inhibition of CA II is brought about by an inhibitor's ability to bind to the catalytic Zn^{2+} in the CA active site and mimic the tetrahedral transition state^{47,49,50}.

There are important differences in inhibition between the two isoenzymes. The main difference is found in the active site architectures of the two hCA isoenzymes and is due to the presence of more histidine residues in the CA I isoform⁴⁷.

In addition to the Zn^{2+} binding ligands (His 94, His 96 and His 119) discussed in the introduction, the His 64 residue of CA I play an important role in catalysis. Another difference between the two isozymes is that CA II contains a histidine cluster consisting of the following residues: His 64, His 4, His 3, His 10, His 15 and His 17 which are absent in CA I. Hence, these two isozymes exhibit different affinities for the inhibitors. In general, CA II has a higher affinity for the inhibitor than CA I⁴⁷.

hCA I is highly abundant in red blood cells and is found in many tissues but its precise physiological function is unknown. CA I is associated with cerebral and retinal edema; thus, the inhibition of CA I may be a valuable tool for fighting these conditions. The physiologically predominant cytosolic isoform hCA II is ubiquitous, and it is associated with several

diseases including epilepsy, edema, glaucoma and altitude sickness^{56,57,105}.

AZA is a well-known example of a clinically established CAI^{106,107} and in recent years we have reported its strong inhibition of both human cytosolic CA I and II. CAI effects are also exhibited by a wide spectrum of phenolic compounds including melatonin⁴⁰, morphine⁴¹, vitamin E⁷⁴, CAPE⁸⁴, anti-oxidant phenols¹⁰⁰, phenolic acids⁹⁸, natural product polyphenols and phenolic acids⁹⁶, natural phenolic compounds^{51,92,95}, anti-oxidant polyphenol products^{92,95} (3,4-dihydroxyphenyl)(2,3,4-trihydroxyphenyl)methanone and its derivatives⁵², natural and synthetic bromophenols^{57,91,108}, novel sulfonamide derivatives of aminoindanes and anilines⁴⁴, novel phenolic sulfamides¹⁰⁸, novel phenolic benzylamine derivatives⁴⁵, sulfonamide derivatives⁶⁰ and novel sulfamide analogues of dopamine-related compounds³⁸, new benzotropone derivatives⁵⁰, guaiacol and catechol derivatives⁵⁵, capsaicin¹⁰⁹, hydroquinone¹¹⁰ and brominated diphenylmethanone and its derivatives⁴⁶, novel sulfamides and sulfonamides incorporating a tetralin scaffold³⁹. These extensive studies indicate the importance of CA I and II isoenzyme inhibitors.

AChE was very strongly inhibited by taxifolin (Table 1). Taxifolin had an IC₅₀ value of 30.1 nM and a K_i value of 16.7 ± 3.9 nM (Figure 3). On the other hand, donepezil hydrochloride, which is used to the treatment of mild-to-moderate AD and various other memory impairments, had been shown to lower AChE inhibition activity (IC₅₀: 55 nM)¹⁰⁶. Donepezil hydrochloride contains *N*-benzylpiperidine and an indanone moiety that shows longer and more selective action.

Conclusions

Taxifolin demonstrated unique inhibition profiles against both CA isoforms I and II. These results demonstrated that in the light of the high homology between these two CAs, they exhibit similar activity. Taxifolin was first identified as a potent CAI because phenolic compounds with aromatic rings have previously been identified as inhibitors of CA. In this study, nanomolar levels of K_i and IC₅₀ values were observed for taxifolin. We show that taxifolin is a selective inhibitor for both cytosolic CA isoenzymes. These results clearly indicate the potential for use of bioactive taxifolin to identifying more CAIs and for eventually targeting additional isoforms. Additionally, taxifolin had effective AChE inhibition properties and it can be a good candidate for the treatment of mild-to-moderate AD and various other memory impairments.

Declaration of interest

The authors declare no conflict of interest. I.G. and S.H.A. would like to extend his sincere appreciation to the Deanship of Scientific Research at King Saud University for its funding of this research through the Research Group Project No. RGP-VPP-254.

References

1. Rice-Evans CA, Miller NJ, Paganga G. Structure antioxidant activity relationships of flavanoids and phenolic acids. *Free Radical Biol Med* 1996;20:933–56.
2. Gülçin İ. Antioxidant activity of food constituents – an overview. *Arch Toxicol* 2012;86:345–91.
3. Makarova K, Lastawska K, Wagner D, Wawer I. ESR study of spin trapping in Fenton media in the presence of taxifolin. *J Mol Struct* 2014;1067:27–36.
4. Gülçin İ, Daştan A. Synthesis of dimeric phenol derivatives and determination of in vitro antioxidant and radical scavenging activities. *J Enzyme Inhib Med Chem* 2007;22:685–95.
5. Ak T, Gülçin İ. Antioxidant and radical scavenging properties of curcumin. *Chem Biol Interact* 2008;174:27–37.
6. Gülçin İ, Büyükokuroğlu ME, Oktay M, Küfrevioğlu Öİ. On the in vitro antioxidant properties of melatonin. *J Pineal Res* 2002;33:167–71.
7. Gülçin İ, Büyükokuroğlu ME, Küfrevioğlu Öİ. Metal chelating and hydrogen peroxide scavenging effects of melatonin. *J Pineal Res* 2003;34:278–81.
8. Gülçin İ, Beydemir S, Büyükokuroğlu ME. *In vitro* and *in vivo* effects of dantrolene on carbonic anhydrase enzyme activities. *Biol Pharm Bull* 2004;27:613–16.
9. Gülçin İ, Beydemir Ş, Alici HA, et al. In vitro antioxidant properties of morphine. *Pharmacol Res* 2004;49:59–66.
10. Gülçin İ, Berashvili D, Gepdiremen A. Antiradical and antioxidant activity of total anthocyanins from *Perilla pankinensis* decne. *J Ethnopharmacol* 2005;101:287–93.
11. Gülçin İ, Elias R, Gepdiremen A, Boyer L. Antioxidant activity of lignans from fringe tree (*Chionanthus virginicus* L.). *Eur Food Res Technol* 2006;223:759–67.
12. Göçer H, Gülçin İ. Caffeic acid phenethyl ester (CAPE): correlation of structure and antioxidant properties. *Int J Food Sci Nutr* 2011;62:821–5.
13. Gülçin İ, Beydemir Ş, Çoban TA, Ekinci D. The inhibitory effect of dantrolene sodium and propofol on 6-phosphogluconate dehydrogenase from rat erythrocyte. *Fresen Environ Bull* 2008;17:1283–7.
14. Gülçin İ, Elias R, Gepdiremen A, et al. Antioxidant secoiridoids from fringe tree (*Chionanthus virginicus* L.). *Wood Sci Technol* 2009;43:195–212.
15. Şişecioglu M, Çankaya M, Gülçin İ, Özdemir M. The Inhibitory effect of propofol on lactoperoxidase. *Protein Peptide Lett* 2009;16:46–9.
16. Gülçin İ. Antioxidant activity of caffeic acid (3,4-dihydroxycinnamic acid). *Toxicology* 2006;217:213–20.
17. Gülçin İ. Antioxidant and antiradical activities of L-carnitine. *Life Sci* 2006;78:803–11.
18. Şişecioglu M, Çankaya M, Gülçin İ, Özdemir M. Interactions of melatonin and serotonin to lactoperoxidase enzyme. *J Enzyme Inhib Med Chem* 2010;25:779–83.
19. Gülçin İ. Comparison of in vitro antioxidant and antiradical activities of L-tyrosine and L-Dopa. *Amino Acids* 2007;32:431–8.
20. Gülçin İ. Measurement of antioxidant ability of melatonin and serotonin by the DMPD and CUPRAC methods as trolox equivalent. *J Enzyme Inhib Med Chem* 2008;23:871–6.
21. Şişecioglu M, Gülçin İ, Çankaya M, Özdemir H. The inhibitory effects of L-adrenaline on lactoperoxidase enzyme (LPO) purified from buffalo milk. *Int J Food Propert* 2012;15:1182–9.
22. Gülçin İ. Antioxidant activity of L-adrenaline: an activity-structure insight. *Chem Biol Interact* 2009;179:71–80.
23. Gülçin İ. Antioxidant properties of resveratrol: a structure-activity insight. *Innov Food Sci Emerg* 2010;11:210–18.
24. Gülçin İ. Antioxidant activity of eugenol – a structure and activity relationship study. *J Med Food* 2011;14:975–85.
25. Kim NC, Graf TN, Sparacino CM, et al. Complete isolation and characterization of silybins and isosilybins from milk thistle (*Silybum marianum*). *Org Biomol Chem* 2003;1:1684–9.
26. Weidmann AE. Dihydroquercetin: more than just an impurity? *Eur J Pharmacol* 2012;684:19–26.
27. Vladimirov YA, Proskurnina EV, Demin EM, et al. Dihydroquercetin (taxifolin) and other flavonoids as inhibitors of free radical formation at key stages of apoptosis. *Biochemistry (Mosc)* 2009;74:301–7.
28. Wang YH, Wang WY, Chang CC, et al. Taxifolin ameliorates cerebral ischemia-reperfusion injury in rats through its anti-oxidative effect and modulation of NF-kappa B activation. *J Biomed Sci* 2006;13:127–41.
29. Haraguchi H, Ohmi I, Fukuda A, et al. Inhibition of aldose reductase and sorbitol accumulation by astilbin and taxifolin dihydroflavonols in *Engelhardtia chrysolepis*. *Biosci Biotechnol Biochem* 1997;61:651–4.
30. Sun X, Chen RC, Yang ZH, et al. Taxifolin prevents diabetic cardiomyopathy in vivo and in vitro by inhibition of oxidative stress and cell apoptosis. *Food Chem Toxicol* 2014;63:221–32.
31. Arutyunyan TV, Korystova AF, Kublik LN, et al. Effects of taxifolin on the activity of angiotensin-converting enzyme and reactive oxygen and nitrogen species in the aorta of aging rats and rats treated with the nitric oxide synthase inhibitor and dexamethasone. *Age* 2013;35:2089–97.

32. Middleton Jr E, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. *Pharmacol Rev* 2000;52:673–51.
33. Cermak R, Wolfram S. The potential of flavonoids to influence drug metabolism and pharmacokinetics by local gastrointestinal mechanisms. *Curr Drug Metab* 2006;7:729–44.
34. Eger S, Rimbach G. Which sources of flavonoids: complex diets or dietary supplements? *Adv Nutr* 2011;2:8–14.
35. Boušová I, Hájek J, Dršata J, Skálová L. Naturally occurring flavonoids as inhibitors of purified cytosolic glutathione S-transferase. *Xenobiotica* 2012;42:872–9.
36. Supuran CT, Scozzafava A. Carbonic anhydrases as targets for medicinal chemistry. *Bioorg Med Chem* 2007;15:4336–50.
37. Zolnowska B, Slawinska J, Pogorzelska A, et al. Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methyl benzenesulfonyl) guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII. *Eur J Med Chem* 2014;71:135–47.
38. Aksu K, Nar M, Tanc M, et al. The synthesis of sulfamide analogues of dopamine related compounds and their carbonic anhydrase inhibitory properties. *Bioorg Med Chem* 2013;21:2925–31.
39. Akincioglu A, Topal M, Gülçin I, Goksu S. Novel sulfamides and sulfonamides incorporating tetralin scaffold as carbonic anhydrase and acetylcholine esterase inhibitors. *Arch Pharm* 2014;347:68–76.
40. Beydemir S, Gülçin I. Effect of melatonin on carbonic anhydrase from human erythrocyte in vitro and from rat erythrocyte in vivo. *J Enzyme Inhib Med Chem* 2004;19:193–7.
41. Coban TA, Beydemir S, Gülçin I, Ekinci D. Morphine inhibits erythrocyte carbonic anhydrase in vitro and in vivo. *Biol Pharm Bull* 2007;30:2257–61.
42. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. *Nat Rev Drug Discov* 2008;7:168–81.
43. Akbaba Y, Akincioglu A, Gocer H, et al. Carbonic anhydrase inhibitory properties of novel sulfonamide derivatives of aminoin-danes and aminotetralins. *J Enzyme Inhib Med Chem* 2014;29: 35–42.
44. Akbaba Y, Bastem E, Topal F, et al. Synthesis and carbonic anhydrase inhibitory effects of novel sulfamides derived from 1-aminoin-danes and anilines. *Arch Pharm* 2014;347:950–7.
45. Cetinkaya Y, Gocer H, Goksu S, Gülçin I. Synthesis and carbonic anhydrase isoenzymes inhibitory effects of novel benzylamine derivatives. *J Enzyme Inhib Med Chem* 2014;29:168–74.
46. Çetinkaya Y, Göçer H, Gülçin İ, Menzek A. Synthesis and carbonic anhydrase isoenzymes inhibitory effects of brominated diphenyl-methanone and its derivatives. *Arch Pharm* 2014;347:354–9.
47. Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. *Expert Opin Ther Pat* 2000;10:575–600.
48. Mincione F, Scozzafava A, Supuran CT. In drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. Hoboken: Wiley; 2009:139.
49. Supuran CT. Carbonic anhydrase inhibitors. *Bioorg Med Chem Lett* 2010;20:3467–74.
50. Güney M, Coskun A, Topal F, et al. Oxidation of cyanobenzocycloheptatrienes: synthesis, photooxygenation reaction and carbonic anhydrase isoenzymes inhibition properties of some new benzo-tropone derivatives. *Bioorg Med Chem* 2014;22:3537–43.
51. Gülçin I, Beydemir Ş. Phenolic compounds as antioxidants: carbonic anhydrase isoenzymes inhibitors. *Mini Rev Med Chem* 2013;13: 408–30.
52. Nar M, Cetinkaya Y, Gulcin I, Menzek A. (3,4-Dihydroxyphenyl)(2,3,4-trihydroxyphenyl)methanone and its derivatives as carbonic anhydrase isoenzymes inhibitors. *J Enzyme Inhib Med Chem* 2013;28:402–6.
53. De Simone G, Di Fiore A, Supuran CT. Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? *Curr Pharm Des* 2008;14:655–60.
54. Göksu S, Naderi A, Akbaba Y, et al. Carbonic anhydrase inhibitory properties of novel benzylsulfamides using molecular modeling and experimental studies. *Bioorg Chem* 2014;56:75–82.
55. Scozzafava A, Passaponti M, Supuran CT, Gülçin İ. Carbonic anhydrase inhibitors: guaiacol and catechol derivatives effectively inhibit certain human carbonic anhydrase isoenzymes (hCA I, II, IX, and XII). *J Enzyme Inhib Med Chem* 2015; DOI:10.3109/14756366.2014.956310.
56. Sethi KK, Verma SM, Tanc M, et al. Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophenalimide moieties. *Bioorg Med Chem* 2014;22:1586–95.
57. Boztaş M, Çetinkaya Y, Topal M, et al. Synthesis and carbonic anhydrase isoenzymes I, II, IX, and XII inhibitory effects of dimethoxy-bromophenol derivatives incorporating cyclopropane moieties. *J Med Chem* 2015;58:640–50.
58. Franchi M, Vullo D, Gallori E, et al. Carbonic anhydrase inhibitors: inhibition of human and murine mitochondrial isozymes V with anions. *Bioorg Med Chem Lett* 2003;13:2857–61.
59. Taslimi P, Gulcin İ, Ozgeris B, et al. The human carbonic anhydrase isoenzymes I and II (hCA I and II) inhibition effects of trimethoxyindane derivatives. *J Enzyme Inhib Med Chem* 2015; DOI:10.3109/14756366.2015.1014476.
60. Göçer H, Akıncıoğlu A, Öztaşkın N, et al. Synthesis, antioxidant and antiacetylcholinesterase activities of sulfonamide derivatives of dopamine related compounds. *Arch Pharm* 2013;346:783–92.
61. Gocer H, Akıncıoğlu A, Goksu S, et al. Carbonic anhydrase and acetylcholine esterase inhibitory effects of carbamates and sulfamoylcarbamates. *J Enzyme Inhib Med Chem* 2015;30: 316–20.
62. Fulton MH, Key PB. Acetylcholinesterase inhibition in estuarine fish and invertebrates as an indicator of organophosphorus insecticide exposure and effects. *Environ Toxicol Chem* 2001;20: 37–45.
63. Allam AR, Sridhar GR, Das UN. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease. *Med Hypotheses* 2007; 69:1272–6.
64. Greenblatt HM, Dvir H, Silman I, Sussman JL. Acetylcholinesterase: a multifaceted target for structure-based drug design of anticholinesterase agents for the treatment of Alzheimer's disease. *J Mol Neurosci* 2003;20:369–83.
65. Costa P, Goncalves S, Valentao P, et al. Accumulation of phenolic compounds in in vitro cultures and wild plants of *Lavandula viridis* L'Hér and their antioxidant and anti-cholinesterase potential. *Food Chem Toxicol* 2013;57:69–74.
66. Hobbiger F. The inhibition of acetylcholinesterase by organophosphorus compounds and its reversal. *Proc R Soc Med* 1961;54:403–5.
67. Massoulie J, Pezzementi L, Bon S, et al. Molecular and cellular biology of cholinesterases. *Prog Neurobiol* 1993;41:31–91.
68. Ryu HW, Curtis-Long MJ, Jung S, et al. Anticholinesterase potential of flavonols from paper mulberry (*Broussonetia papyrifera*) and their kinetic studies. *Food Chem* 2012;132:1244–50.
69. Szwajgier D. Anticholinesterase activities of selected polyphenols – a short report. *Pol J Food Nutr Sci* 2014;64:59–64.
70. Krikorian R, Shidler MD, Nash TA, et al. Blueberry supplementation improves memory in older adults. *J Agric Food Chem* 2010;58: 3996–4000.
71. Gutierrez JM, Carvalho FB, Schetinger MR, et al. Anthocyanins restore behavioral and biochemical changes caused by streptozotocin-induced sporadic dementia of Alzheimer's type. *Life Sci* 2013; 96:7–17.
72. Pervin M, Hasnat MdA, Lee YM, et al. Antioxidant activity and acetylcholinesterase inhibition of grape skin anthocyanin (GSA). *Molecules* 2014;19:9403–18.
73. Zhang DB, Chen JJ, Song QY, et al. Lycodine-type alkaloids from *Lycopodium casuarinoides* and their acetylcholinesterase inhibitory activity. *Molecules* 2014;19:9999–10010.
74. Aras Hisar S, Hisar O, Beydemir S, et al. Effect of vitamin E on carbonic anhydrase enzyme activity in rainbow trout (*Oncorhynchus mykiss*) erythrocytes in vitro and in vivo. *Acta Vet Hung* 2004;52: 413–22.
75. Coban TA, Beydemir S, Gülçin I, Ekinci D. The inhibitory effect of ethanol on carbonic anhydrase isoenzymes: in vivo and in vitro studies. *J Enzyme Inhib Med Chem* 2008;23:266–70.
76. Senturk M, Gülçin I, Beydemir S, et al. *In vitro* inhibition of human carbonic anhydrase I and II isozymes with natural phenolic compounds. *Chem Biol Drug Des* 2011;77:494–9.
77. Atasaver A, Özdemir H, Gülçin İ, Küfrevioğlu Öİ. One-step purification of lactoperoxidase from bovine milk by affinity chromatography. *Food Chem* 2013;136:864–70.
78. Laemmli DK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 1970; 227:680–3.

79. Gülçin I, Kufrevioglu OI, Oktay M. Purification and characterization of polyphenol oxidase from nettle (*Urtica dioica* L.) and inhibition effects of some chemicals on the enzyme activity. *J Enzyme Inhib Med Chem* 2005;20:297–302.
80. Beydemir S, Gülçin I, Hisar O, et al. Effect of melatonin on glucose-6-phosphate dehydrogenase from rainbow trout (*Oncorhynchus mykiss*) erythrocytes in vitro and in vivo. *J Appl Anim Res* 2005; 28:65–8.
81. Hisar O, Beydemir S, Gülçin I, et al. The effect of melatonin hormone on carbonic anhydrase enzyme activity in rainbow trout (*Oncorhynchus mykiss*) erythrocytes in vitro and in vivo. *Turk J Vet Anim Sci* 2005;29:841–5.
82. Verpoorte JA, Mehta S, Edsall JT. Esterase activities of human carbonic anhydrases B and C. *J Biol Chem* 1967;242:4221–9.
83. Coban TA, Beydemir S, Gülçin I, et al. Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms I–XIV. *Bioorg Med Chem* 2009;17:5791–5.
84. Gocer H, Gülçin I. Caffeic acid phenethyl ester (CAPE): a potent carbonic anhydrase isoenzymes inhibitor. *Int J Acad Res* 2013;5: 150–5.
85. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976;72:248–51.
86. Koksall E, Gülçin İ. Purification and characterization of peroxidase from cauliflower (*Brassica oleracea* L.) buds. *Protein Peptide Lett* 2008;15:320–6.
87. Senturk M, Gülçin I, Ciftci M, Kufrevioglu OI. Dantrolene inhibits human erythrocyte glutathione reductase. *Biol Pharm Bull* 2008;31: 2036–9.
88. Lineweaver H, Burk D. The determination of enzyme dissociation constants. *J Am Chem Soc* 1934;56:658–66.
89. Yıldırım A, Atmaca U, Keskin A, et al. N-Acylsulfonamides strongly inhibit human carbonic anhydrase isoenzymes I and II. *Bioorg Med Chem* 2015; DOI:10.1016/j.bmc.2014.12.054.
90. Cetinkaya Y, Gocer H, Menzek A, Gülçin İ. Synthesis and antioxidant properties of (3,4-dihydroxyphenyl)(2,3,4-trihydroxyphenyl)methanone and its derivatives. *Arch Pharm* 2012;345: 323–34.
91. Akbaba Y, Balaydin HT, Menzek A, et al. Synthesis and biological evaluation of novel bromophenol derivatives as carbonic anhydrase inhibitors. *Arch Pharm* 2013;346:447–54.
92. Ozturk Sarikaya SB, Topal F, Senturk M, et al. In vitro inhibition of α -carbonic anhydrase isozymes by some phenolic compounds. *Bioorg Med Chem Lett* 2011;21:4259–62.
93. Ellman GL, Courtney KD, Andres V, Featherston RM. A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem Pharmacol* 1961;7:88–95.
94. Topal M, Gülçin İ. Rosmarinic acid: a potent carbonic anhydrase isoenzymes inhibitor. *Turk J Chem* 2014;38:894–902.
95. Innocenti A, Gülçin İ, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Antioxidant polyphenol natural products effectively inhibit mammalian isoforms I–XV. *Bioorg Med Chem Lett* 2010;20:5050–3.
96. Innocenti A, Ozturk Sarikaya SB, Gülçin I, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I–XIV with a series of natural product polyphenols and phenolic acids. *Bioorg Med Chem* 2010;18:2159–64.
97. Innocenti A, Vullo D, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Interactions of phenols with the 12 catalytically active mammalian isoforms (CA I–XIV). *Bioorg Med Chem Lett* 2008;18:1583–7.
98. Ozturk Sarikaya SB, Gülçin I, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of phenolic acids. *Chem Biol Drug Des* 2010;75:515–20.
99. Khoddami A, Wilkes MA, Roberts TH. Techniques for analysis of plant phenolic compounds. *Molecules* 2013;18:2328–75.
100. Nair SK, Ludwig PA, Christianson DW. Phenol as a carbonic anhydrase inhibitor. *J Am Chem Soc* 1994;116:3659–60.
101. Innocenti A, Vullo D, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I–XIV with a series of substituted phenols including paracetamol and salicylic acid. *Bioorg Med Chem* 2008;16:7424–8.
102. Davis RA, Innocenti A, Poulsen SA, Supuran CT. Carbonic anhydrase inhibitors. Identification of selective inhibitors of the human mitochondrial isozymes VA and VB over the cytosolic isozymes I and II from a natural product-based phenolic library. *Bioorg Med Chem* 2010;18:14–18.
103. Hisar O, Beydemir S, Gülçin I, et al. Effect of low molecular weight plasma inhibitors of rainbow trout (*Oncorhynchus mykiss*) on human erythrocytes carbonic anhydrase-II isozyme activity in vitro and rat erythrocytes in vivo. *J Enzyme Inhib Med Chem* 2005;20:35–9.
104. Akbaba Y, Türkeş C, Polat L, et al. Synthesis and paroxonase activities of novel bromophenols. *J Enzyme Inhib Med Chem* 2013; 28:1073–9.
105. Akincioglu A, Akbaba Y, Gocer H, et al. Novel sulfamides as potential carbonic anhydrase isoenzymes inhibitors. *Bioorg Med Chem* 2013;21:1379–85.
106. Ogilvie JM, Ohlemiller KK, Shah GN, et al. Carbonic anhydrase XIV deficiency produces a functional defect in the retinal light response. *Proc Natl Acad Sci USA* 2007;104:8514–19.
107. Avvaru BS, Busby SA, Chalmers MJ, et al. Apo-human carbonic anhydrase II revisited: implications of the loss of a metal in protein structure, stability, and solvent network. *Biochemistry* 2009;48: 7365–72.
108. Balaydin HT, Gülçin I, Menzek A, et al. Synthesis and antioxidant properties of diphenylmethane derivative bromophenols including a natural product. *J Enzyme Inhib Med Chem* 2010;25:685–95.
109. Arabaci B, Gülçin I, Alwasel S. Capsaicin: a potent inhibitor of carbonic anhydrase isoenzymes. *Molecules* 2014;19:10103–14.
110. Scozzafava A, Kalin P, Supuran CT, et al. The impact of hydroquinone on acetylcholine esterase and certain human carbonic anhydrase isoenzymes (hCA I, II, IX and XII). *J Enzyme Inhib Med Chem* 2015; DOI: 10.3109/14756366.2014.999236.